CA-MANSCAPED
22.10.2020 15:02:07 CEST | Business Wire | Press release
Male grooming. In this day and age, these two words can - and should - mean trimming and tidying up all areas of a man’s body, including the nether regions. You may have thought about it, or even partaken in this all-important activity and reaped the results! But was it as enjoyable as it was effective? And, more importantly, were you equipped with the right tools for the job?
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201022005418/en/
If you are not already familiar with the pioneer below-the-waist grooming and hygiene brand , let us formally introduce you to MANSCAPED™ . This California-based startup has single-handedly disrupted the men’s grooming industry and created a completely new category in the consumer packaged goods space.
Born in 2016, the booming direct-to-consumer (DTC) company designs and develops premium products for groin and body grooming , while upholding a steadfast mission to empower the modern man to unabashedly grab ahold of his situation “down there”. We are proud to report that since inception, the stigma-shattering brand has utterly taken off.
Today, MANSCAPED announces its latest and most extensive expansion yet into the European Union , which augments its reach to 1 billion people worldwide . This follows successful international launches earlier this year into Canada, Australia, New Zealand, and the United Kingdom. With the holidays on the horizon, the perfect present or self-care treat is now just a click away for every lady and gentleman in more than 30 countries worldwide .
“Entering into Europe in one fell swoop is no small feat, but we’re confident we have the infrastructure and high-powered passion to fuel this momentous launch,” said Stephanie Hinze, MANSCAPED’s Senior Director of International Operations. “Sharing the European Union’s values of inclusion and non-discrimination, we believe our trusted brand and superior products have sparked a new era of well-being for all and will continue to propel a movement throughout the region. We’re particularly excited to have laid the groundwork just in time for the holiday season in order to offer only the best tools and formulations to so many more men and women throughout the world.”
If that news doesn’t excite consumers enough, this milestone is coupled with a new product launch that our international fans have been waiting for. That’s right, our very first above-the-waist tool * is now available in over 30 countries! Combine this groundbreaking device with our best-selling below-the-waist trimmer and skincare products, and you have a set of essentials that is a must-have for the men on your list...
Introducing The Performance Package , our newest luxury grooming kit that includes:
The Lawn Mower™ 3.0 - The legendary electric trimmer for the groin and body is the cornerstone of a refined grooming routine. The precision engineered device boasts a 7,000 RPM motor with QuietStroke™ technology and replaceable ceramic blade with MANSCAPED’s SkinSafe™ technology that helps reduce the risk of nicks, cuts, and snags. The 600mA Li-Ion rechargeable battery and waterproof ergonomic design allows for a safe and easy trimming session.
*The Weed Whacker™ - Now Available Internationally - This revolutionary electric ear and nose hair trimmer is a technological masterpiece, redesigning the traditional nose hair taming tool by focusing on maximum performance and comfort, and offering a sleek, ultramodern design. The tool features SkinSafe technology, a 9,000 RPM motor and 360-degree rotary dual-blade system, and intelligently contoured design.
Crop Preserver™ - Ball deodorant is a thing, and it’s life-changing. The anti-chafing formula is infused with cooling aloe vera and controls any stench coming from an unwanted “swamp crotch”.
Crop Reviver™ - This innovative ball toner is the solution for maintaining hygiene and cleanliness on-the-go. The restorative spray relieves high-friction areas and post-shave irritation with just a spritz or two.
As a leading DTC brand, MANSCAPED offers a one-stop-shop online where customers can browse the full collection and purchase items a la cart or as part of a bundle - all with guaranteed free shipping. For our new consumers residing in Europe, please visit eu.manscaped.com to learn more and join the MANSCAPED Movement today!
About MANSCAPED™:
Founded in 2016, San Diego, California-based MANSCAPED is the global leader in men's grooming and hygiene below-the-waist. The product range includes only the best tools, formulations, and accessories for a simple and effective male grooming routine. MANSCAPED offers direct-to-consumer shipping in more than 30 countries, spanning the United States, Canada, Australia, New Zealand, the United Kingdom, and the European Union. Retail placement includes Target and Best Buy locations throughout the U.S., with further retail availability coming soon. MANSCAPED.com is a one-stop shopping destination for men looking for a brand that is focused on the needs of what has, for too long, been a sensitive and often taboo subject. For more information, visit the website or follow on Facebook , Instagram , Twitter , TikTok , YouTube , and Triller.
View source version on businesswire.com: https://www.businesswire.com/news/home/20201022005418/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 20:00:00 CET | Press release
Phase 3 data from the STOP-HS program demonstrate povorcitinib’s substantial and durable clinical efficacy through Week 54 in patients with moderate to severe hidradenitis suppurativa (HS). Through Week 54, clinically meaningful and durable responses were observed across all groups in both STOP-HS1 and STOP-HS2, with up to 71.4% of patients achieving HiSCR50. Improvements in clinical responses across high stringent thresholds were observed, with up to 57% of participants achieving HiSCR75 and up to 29% of participants achieving HiSCR100. Povorcitinib treatment led to consistent reductions across key inflammatory lesion types, with full resolution (ANdT=0) achieved in up to 20% of patients. Additionally, clinically meaningful improvements in quality-of-life measures, including skin pain and fatigue, were observed at Week 54. The overall safety profile of povorcitinib through 54 weeks is consistent with previously reported data, and both doses were well tolerated. Incyte (Nasdaq:INCY) to
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 20:00:00 CET | Press release
About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater PASI 75 response rate versus placebo was observed as early as week 4 Safety profile consistent with Phase 2b studies with no new safety signals identified Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham,
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 16:00:00 CET | Press release
Pharmacokinetics, safety and efficacy clinical study data show that nemolizumab achieved clinically meaningful reductions in skin lesions and itch through Week 16, which were sustained up to a year in children aged 2 to 11 with moderate-to-severe atopic dermatitis1 These findings reinforce the previously established safety and efficacy of nemolizumab in adults and adolescents with moderate-to-severe atopic dermatitis, for which it is approved by multiple global regulatory authorities2,3 Up to 25% of children are affected by atopic dermatitis, and currently there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis4,5 Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-break
Angelalign Technology (6699.HK)Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 20:56:00 CET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti
Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 18:46:00 CET | Press release
Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom